Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019

Published:2020-05-11 Issue:7 Volume:43 Page:e79-e80
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Liu Jiaqing¹²³⁴,Zhou Huaqiang¹²³,Zhang Yaxiong¹²³,Fang Wenfeng¹²³,Yang Yunpeng¹²³,Huang Yan¹²³,Zhang Li¹²³^ORCID

Affiliation:

1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

2. State Key Laboratory of Oncology in South China, Guangzhou, China

3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

4. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

Funder

National Key R&D Program of China

Science and Technology Program of Guangdong

Chinese National Natural Science Foundation

Science and Technology Program of Guangzhou

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/43/7/e79/630639/dc200459.pdf

Reference6 articles.

1. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018

2. Immune-related adverse events associated with immune checkpoint blockade;Postow;N Engl J Med,2018

3. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors;Stamatouli;Diabetes,2018

4. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus;Clotman;J Clin Endocrinol Metab,2018

5. Increased reporting of immune checkpoint inhibitor-associated Diabetes;Wright;Diabetes Care,2018

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitors-Associated Diabetes and Ketoacidosis Were Found in FDA Adverse Event Reporting System: A Real-World Evidence Database Study;Endocrine Practice;2024-09

2. Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature;Diabetology International;2024-04-18

3. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option;Journal of Oncology Pharmacy Practice;2024-03-28

4. Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report;Endocrine;2024-03-19

5. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria;Diseases;2024-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3